デフォルト表紙
市場調査レポート
商品コード
1433621

バイオマーカーの市場規模、シェア、動向分析レポート:タイプ別、製品別、用途別、疾患別、地域別、セグメント別予測、2024年~2030年

Biomarkers Market Size, Share & Trends Analysis Report By Type (Efficacy, Validation), By Product, By Application (Drug Discovery & Development, Personalized Medicine), By Disease, By Region, And Segment Forecasts, 2024 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
バイオマーカーの市場規模、シェア、動向分析レポート:タイプ別、製品別、用途別、疾患別、地域別、セグメント別予測、2024年~2030年
出版日: 2024年01月24日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオマーカー市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、バイオマーカーの世界市場規模は2024年から2030年にかけて13.36%のCAGRを記録し、2030年には1,942億1,000万米ドルに達する見込みです。

製薬企業やバイオテクノロジー企業による研究開発投資の増加、CRO(医薬品開発業務受託機関)の増加、新興国における臨床試験コストの低下が業界の主な促進要因となっています。加えて、主要企業は生産能力を高め、製品提供のアウトリーチを促進するために様々な戦略を活用しています。2022年6月、ペイジはヤンセンとの提携を発表し、ヤンセンが開発した(H&E)ベースの(AI)搭載バイオマーカー検査で、膀胱がん患者における実用的なFGFR3およびFGFR2のゲノム変化をスクリーニングする可能性を評価します。

がん、糖尿病、心血管障害などの慢性疾患の有病率の増加は、業界の成長を促進すると予想されています。米国がん協会によると、2022年には米国で推定190万人のがん患者が新たに登録され、609,360人が死亡しました。世界で最も多いのは乳がんと肺がんです。さらに、Institute for Health Metrics and Evaluationが2020年に発表した報告書によると、心血管疾患は年間約1,890万人の死亡の原因となっています。新たな診断バイオマーカーの特定に焦点を当てた調査の増加が、業界の成長を後押ししています。例えば、2022年2月、日本の科学者は悪性胸膜中皮腫に適応のある2つの新しい診断組織バイオマーカー、PHGDHとTRIM29を発見しました。

これらの薬剤は中皮腫の迅速診断に使用でき、医師が中皮腫と他のがんを区別するのに役立ちます。さらに2020年1月には、Journal of Nuclear Medicine誌に掲載された新進の調査研究が、いくつかの乳がんバイオマーカーの可能性について論じています。この研究で認識された注目すべき識別しやすい画像バイオマーカーは18F-FDG PETでした。さらに、COVID-19の大流行は、病気の発見と治療を促進するためのバイオマーカーの使用を奨励しています。例えば、2021年3月、Tiger Tech COVID Plus Monitorと名付けられた新しいバイオマーカーベースのスクリーニング装置が米国FDAによって承認されました。

この装置は、5歳以上のCOVID-19およびその他の凝固亢進・炎症性疾患のバイオマーカー同定に使用できます。さらに、主要参入企業によるさまざまな戦略的イニシアチブが需要を満たすと予想されています。例えば、2022年8月、ロシュは、メルクの免疫療法キイトルーダによる治療の対象となるpMMR子宮内膜がん患者およびdMMR固形がん患者を検出するためのベンタナMMR RxDxパネルの米国FDA承認を取得しました。今回のVENTANA MMR RxDx Panelの承認は、同社が最近発売したパネルのラベル拡大です。また、2021年12月、Siemens HealthineersはFreenomeと提携し、同社の既存のイメージング技術を拡張するため、早期乳がんの検出に適した新規マーカーを特定しました。

バイオマーカー市場レポートハイライト

  • 安全性セグメントは、創薬および薬剤開発における安全性バイオマーカーの採用増加により、2023年に37.62%の最大売上シェアを占めました。
  • 有効性バイオマーカー分野は、研究活動促進のための戦略的共同研究の増加により、2024年から2030年にかけて最も速いCAGRで成長する見込み。
  • 創薬・開発分野は、市場参入企業による広範な研究開発努力と創薬におけるバイオマーカーの採用増加により、2023年の市場を独占しました。
  • がん分野は2023年に市場をリードし、2024年から2030年までその優位性を維持すると予測されます。しかし、神経疾患分野は予測期間中に最も速いCAGRを記録すると予測されます。
  • アジア太平洋地域は、主要企業による投資の高まりと、同地域における疾患有病率の増加により、2024年から2030年にかけて最も速いCAGRを達成すると予測されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオマーカー市場:変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • バイオマーカー市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析

第4章 バイオマーカー市場:タイプの推定・動向分析

  • タイプの市場シェア、2023年および2030年
  • セグメントダッシュボード
  • タイプ別の世界のバイオマーカー市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 バイオマーカー市場:製品の推定・動向分析

  • 製品の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 製品別の世界のバイオマーカー市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 バイオマーカー市場:用途の推定・動向分析

  • 用途の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 用途別の世界のバイオマーカー市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第7章 バイオマーカー市場:疾患の推定・動向分析

  • 疾患の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 疾患別の世界のバイオマーカー市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第8章 バイオマーカー市場:地域の推定・動向分析

  • 地域の市場シェア分析、2023年および2030年
  • 地域の市場ダッシュボード
  • 世界の地域の市場スナップショット
  • 市場規模と予測動向分析、2018年から2030年まで
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第9章 競合情勢

  • 主要市場参入企業別の最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Epigenomics AG
    • General Electric
    • Johnson &Johnson Services, Inc.
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories, Inc.
    • Siemens Healthineers AG
    • QIAGEN
    • Merck KGaA
    • PerkinElmer Inc.
    • Agilent Technologies, Inc.
    • Eurofins Scientific
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 4 North America Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 5 North America Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 6 North America Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 7 North America Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 8 U.S. Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 11 U.S. Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 12 Canada Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 Canada Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 14 Canada Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 16 Europe Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 19 Europe Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 20 Europe Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 21 Germany Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Germany Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 23 Germany Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 24 Germany Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 25 UK Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 UK Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 27 UK Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 28 UK Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 29 France Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 France Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 31 France Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 32 France Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 33 Spain Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Spain Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 36 Spain Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 37 Italy Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Italy Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 39 Italy Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 40 Italy Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 41 Denmark Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 42 Denmark Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 43 Denmark Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 44 Denmark Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 45 Norway Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 47 Norway Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 48 Norway Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 49 Sweden Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Sweden Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 51 Sweden Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 52 Sweden Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 58 Japan Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Japan Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 60 Japan Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 61 Japan Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 62 China Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 China Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 64 China Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 65 China Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 66 India Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 67 India Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 68 India Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 69 India Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 70 South Korea Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 71 South Korea Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 72 South Korea Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 73 South Korea Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 74 Australia Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 Australia Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 76 Australia Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 77 Australia Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 78 Thailand Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Thailand Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 80 Thailand Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 81 Thailand Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 82 Latin America Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 83 Latin America Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 84 Latin America Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 85 Latin America Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 86 Latin America Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 87 Brazil Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 88 Brazil Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 89 Brazil Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 90 Brazil Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 91 Argentina Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 Argentina Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 93 Argentina Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 94 Argentina Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 95 Mexico Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 96 Mexico Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 97 Mexico Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 98 Mexico Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa Biomarkers Market, By Country, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 103 Middle East and Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 104 South Africa Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 South Africa Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 106 South Africa Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 107 South Africa Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 112 Kuwait Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 113 Kuwait Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 114 Kuwait Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Biomarkers Market, By Disease, 2018 - 2030 (USD Million)
  • Table 116 UAE Biomarkers Market, By Type, 2018 - 2030 (USD Million)
  • Table 117 UAE Biomarkers Market, By Product, 2018 - 2030 (USD Million)
  • Table 118 UAE Biomarkers Market, By Application, 2018 - 2030 (USD Million)
  • Table 119 UAE Biomarkers Market, By Disease, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary Interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary Interviews in APAC
  • Fig. 7 Primary Interviews in Latin America
  • Fig. 8 Primary Interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Biomarkers market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Biomarkers market driver impact
  • Fig. 20 Biomarkers market restraint impact
  • Fig. 21 Biomarkers market strategic initiatives analysis
  • Fig. 22 Biomarkers market: Type movement analysis
  • Fig. 23 Biomarkers market: Type outlook and key takeaways
  • Fig. 24 Safety biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 25 Efficacy biomarkers agents estimates and forecast, 2018 - 2030
  • Fig. 26 Predictive biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 27 Surrogate biomarkers estimates and forecast, 2018 - 2030
  • Fig. 28 Pharmacodynamic biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 29 Prognostics biomarkers estimates and forecast, 2018 - 2030
  • Fig. 30 Validation biomarkers estimates and forecast, 2018 - 2030
  • Fig. 31 Biomarkers market: Product movement analysis
  • Fig. 32 Biomarkers market: Product outlook and key takeaways
  • Fig. 33 Consumables market estimates and forecast, 2018 - 2030
  • Fig. 34 Services estimates and forecast, 2018 - 2030
  • Fig. 35 Software market estimates and forecast, 2018 - 2030
  • Fig. 36 Biomarkers market: Disease movement analysis
  • Fig. 37 Biomarkers market: Disease outlook and key takeaways
  • Fig. 38 Diagnostics market estimates and forecast, 2018 - 2030
  • Fig. 39 Drug discovery and development estimates and forecast, 2018 - 2030
  • Fig. 40 Personalized medicine market estimates and forecast, 2018 - 2030
  • Fig. 41 Disease risk assessment estimates and forecast, 2018 - 2030
  • Fig. 42 Others market estimates and forecast, 2018 - 2030
  • Fig. 43 Biomarkers market: Disease movement analysis
  • Fig. 44 Biomarkers market: Disease outlook and key takeaways
  • Fig. 45 Cancer market estimates and forecast, 2018 - 2030
  • Fig. 46 Cardiovascular diseases estimates and forecast, 2018 - 2030
  • Fig. 47 Neurological diseases market estimates and forecast, 2018 - 2030
  • Fig. 48 Immunological diseases estimates and forecast, 2018 - 2030
  • Fig. 49 Others market estimates and forecast, 2018 - 2030
  • Fig. 50 Global ophthalmic drugs market: Regional movement analysis
  • Fig. 51 Global ophthalmic drugs market: Regional outlook and key takeaways
  • Fig. 52 Global ophthalmic drugs market share and leading players
  • Fig. 53 North America market share and leading players
  • Fig. 54 Europe market share and leading players
  • Fig. 55 Asia Pacific market share and leading players
  • Fig. 56 Latin America market share and leading players
  • Fig. 57 Middle East & Africa market share and leading players
  • Fig. 58 North America: SWOT
  • Fig. 59 Europe SWOT
  • Fig. 60 Asia Pacific SWOT
  • Fig. 61 Latin America SWOT
  • Fig. 62 MEA SWOT
  • Fig. 63 North America, by country
  • Fig. 64 North America
  • Fig. 65 North America market estimates and forecasts, 2018 - 2030
  • Fig. 66 U.S. key country dynamics
  • Fig. 67 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 68 Canada key country dynamics
  • Fig. 69 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 70 Europe
  • Fig. 71 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 72 UK key country dynamics
  • Fig. 73 UK market estimates and forecasts, 2018 - 2030
  • Fig. 74 Germany key country dynamics
  • Fig. 75 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 76 France key country dynamics
  • Fig. 77 France market estimates and forecasts, 2018 - 2030
  • Fig. 78 Italy key country dynamics
  • Fig. 79 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 80 Spain key country dynamics
  • Fig. 81 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 82 Denmark key country dynamics
  • Fig. 83 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 84 Sweden key country dynamics
  • Fig. 85 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 86 Norway key country dynamics
  • Fig. 87 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 88 Asia Pacific
  • Fig. 89 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 90 China key country dynamics
  • Fig. 91 China market estimates and forecasts, 2018 - 2030
  • Fig. 92 Japan key country dynamics
  • Fig. 93 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 94 India key country dynamics
  • Fig. 95 India market estimates and forecasts, 2018 - 2030
  • Fig. 96 Thailand key country dynamics
  • Fig. 97 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 98 South Korea key country dynamics
  • Fig. 99 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 100 Australia key country dynamics
  • Fig. 101 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 102 Latin America
  • Fig. 103 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 104 Brazil key country dynamics
  • Fig. 105 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 106 Mexico key country dynamics
  • Fig. 107 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 108 Argentina key country dynamics
  • Fig. 109 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 110 Middle East and Africa
  • Fig. 111 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 112 South Africa key country dynamics
  • Fig. 113 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 114 Saudi Arabia key country dynamics
  • Fig. 115 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 116 UAE key country dynamics
  • Fig. 117 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 118 Kuwait key country dynamics
  • Fig. 119 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 120 Market share of key market players- Biomarkers market
目次
Product Code: 978-1-68038-979-1

Biomarkers Market Growth & Trends:

The global biomarkers market size is expected to reach USD 194.21 billion by 2030, registering a CAGR of 13.36% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising R&D investments by pharmaceutical and biotechnology companies, increasing number of Contract Research Organizations(CROs), and declining cost of clinical trials in emerging economies are the major driving factors for the industry. In addition, key players leverage various strategies to increase their production capabilities and promote the outreach of their product offerings. In June 2022, Paige announced its collaboration with Janssen to evaluate the potential of an (H&E)-based, (AI)-powered biomarker test, developed by Janssen, to screen for actionable FGFR3 and FGFR2 genomic alterations in patients with bladder cancer.

The increasing prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders is anticipated to fuel industry growth. According to the American Cancer Society, in 2022, an estimated 1.9 million new cancer cases were registered in the U.S., accounting for 609,360 deaths. Breast and lung cancers were observed as the most common ones worldwide. In addition, according to a report published in 2020 by the Institute for Health Metrics and Evaluation, cardiovascular diseases cause about 18.9 million deaths annually. Increasing research focused on the identification of new diagnostic biomarkers is fueling the industry's growth. For instance, in February 2022, Japanese scientists found two new diagnostic tissue biomarkers, PHGDH and TRIM29, indicated for malignant pleural mesothelioma.

These agents can be used to diagnose mesothelioma quickly and help doctors in differentiating between mesothelioma and other cancers. Moreover, in January 2020, a nascent research study published in the Journal of Nuclear Medicine discussed the potential of several breast cancer biomarkers. A notable and easily identifiable imaging biomarker recognized in the study was 18F-FDG PET. Moreover, the COVID-19 pandemic has encouraged the use of biomarkers for facilitating the detection & treatment of the disease. For instance, in March 2021, a new biomarker-based screening device, named Tiger Tech COVID Plus Monitor, was approved by the U.S. FDA.

The device can be used for the identification of biomarkers for COVID-19 and other hypercoagulable & hyperinflammatory conditions in individuals aged 5 years & above. Furthermore, various strategic initiatives undertaken by leading participants are anticipated to cater to demand. For instance, in August 2022, Roche received the U.S. FDA approval for VENTANA MMR RxDx Panel to detect pMMR endometrial cancer patients and dMMR solid tumor patients eligible for treatment with Merck's immunotherapy Keytruda. This approval for the VENTANA MMR RxDx Panel is a label expansion of the company's recent on-market panel. Also, in December 2021, Siemens Healthineers partnered with Freenome to identify novel suitable markers for the detection of early breast cancer to expand its existing imaging technologies.

Biomarkers Market Report Highlights:

  • The safety segment held the largest revenue share of 37.62% in 2023 owing to the increased adoption of safety biomarkers in drug discovery and development
  • The efficacy biomarkers segment is expected to grow at the fastest CAGR from 2024 to 2030 due to a rise in strategic collaborations for promoting research activities
  • The drug discovery & development segment dominated the market in 2023 due to the extensive R&D efforts taken by leading participants, and the rising adoption of biomarkers in drug discovery
  • The cancer segment led the market in 2023 and is expected to retain its dominance from 2024 to 2030. . However, the neurological diseases segment is anticipated to record the fastest CAGR over the forecast years
  • Asia Pacific is anticipated to attain the fastest CAGR from 2024 to 2030 due to the rising investments by key players and increasing disease prevalence in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Application
    • 1.2.4. Disease
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for Primary Interviews in North America
      • 1.4.5.2. Data for Primary Interviews in Europe
      • 1.4.5.3. Data for Primary Interviews in Asia Pacific
      • 1.4.5.4. Data for Primary Interviews in Latin America
      • 1.4.5.5. Data for Primary Interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type and product outlook
    • 2.2.2. Application and disease outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing funding for biomarkers
      • 3.2.1.2. Increasing prevalence for chronic diseases
      • 3.2.1.3. Technological advancement
      • 3.2.1.4. Growing importance of companion diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of reimbursement policies for biomarkers
      • 3.2.2.2. High capital investment and lengthy timelines for biomarker development
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Emergence of personalized medicine
      • 3.2.3.2. Emerging economies
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Challenges associated with biomarkers validation
      • 3.2.4.2. Technical issues related to sample collection and storage
  • 3.3. Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
      • 3.3.3.1. Selling price of biomarker by top players

Chapter 4. Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Biomarkers Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Safety biomarkers
      • 4.4.1.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Efficacy biomarkers
      • 4.4.2.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Predictive biomarkers
      • 4.4.3.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Surrogate biomarkers
      • 4.4.4.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Pharmacodynamic biomarkers
      • 4.4.5.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Prognostics biomarkers
      • 4.4.6.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Validation biomarkers
      • 4.4.7.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Biomarkers Market: Product Estimates & Trend Analysis

  • 5.1. Product Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Biomarkers Market by Product Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Consumables
      • 5.4.1.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Services
      • 5.4.2.1. Services market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Software
      • 5.4.3.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Biomarkers Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Diagnostics
      • 6.4.1.1. Diagnostics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.2. Drug Discovery and Development
      • 6.4.2.1. Drug discovery and development market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Personalized Medicine
      • 6.4.3.1. Personalized medicine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.4. Disease Risk Assessment
      • 6.4.4.1. Disease risk assessment market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Biomarkers Market: Disease Estimates & Trend Analysis

  • 7.1. Disease Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Biomarkers Market by Disease Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Cancer
      • 7.4.1.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.2. Safety biomarkers
      • 7.4.1.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.3. Efficacy biomarkers
      • 7.4.1.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.4. Predictive biomarkers
      • 7.4.1.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.5. Surrogate biomarkers
      • 7.4.1.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.6. Pharmacodynamic biomarkers
      • 7.4.1.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.7. Prognostics biomarkers
      • 7.4.1.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.1.8. Validation biomarkers
      • 7.4.1.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2. Cardiovascular Diseases
      • 7.4.2.1. Cardiovascular diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.2. Safety biomarkers
      • 7.4.2.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.3. Efficacy biomarkers
      • 7.4.2.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.4. Predictive biomarkers
      • 7.4.2.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.5. Surrogate biomarkers
      • 7.4.2.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.6. Pharmacodynamic biomarkers
      • 7.4.2.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.7. Prognostics biomarkers
      • 7.4.2.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.2.8. Validation biomarkers
      • 7.4.2.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)Neurological Diseases
      • 7.4.3.1. Neurological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.2. Safety biomarkers
      • 7.4.3.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.3. Efficacy biomarkers
      • 7.4.3.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.4. Predictive biomarkers
      • 7.4.3.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.5. Surrogate biomarkers
      • 7.4.3.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.6. Pharmacodynamic biomarkers
      • 7.4.3.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.7. Prognostics biomarkers
      • 7.4.3.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.3.8. Validation biomarkers
      • 7.4.3.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.4. Immunological Diseases
      • 7.4.4.1. Immunological diseases market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.2. Safety biomarkers
      • 7.4.4.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.3. Efficacy biomarkers
      • 7.4.4.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.4. Predictive biomarkers
      • 7.4.4.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.5. Surrogate biomarkers
      • 7.4.4.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.6. Pharmacodynamic biomarkers
      • 7.4.4.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.7. Prognostics biomarkers
      • 7.4.4.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.4.8. Validation biomarkers
      • 7.4.4.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.5. Others
      • 7.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.2. Safety biomarkers
      • 7.4.5.2.1. Safety biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.3. Efficacy biomarkers
      • 7.4.5.3.1. Efficacy biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.4. Predictive biomarkers
      • 7.4.5.4.1. Predictive biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.5. Surrogate biomarkers
      • 7.4.5.5.1. Surrogate biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.6. Pharmacodynamic biomarkers
      • 7.4.5.6.1. Pharmacodynamic Biomarkers Market Estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.7. Prognostics biomarkers
      • 7.4.5.7.1. Prognostics biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)
      • 7.4.5.8. Validation biomarkers
      • 7.4.5.8.1. Validation biomarkers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Biomarkers Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key Country Dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts for 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. F. Hoffmann-La Roche Ltd.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Abbott
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Epigenomics AG
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. General Electric
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Johnson & Johnson Services, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Thermo Fisher Scientific Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Bio-Rad Laboratories, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Siemens Healthineers AG
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. QIAGEN
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Merck KGaA
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. PerkinElmer Inc.
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Agilent Technologies, Inc.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. Eurofins Scientific
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives